EGFR and non-small cell lung carcinoma: For inoperable NSCLC harboring EGFR mutations, EGFR tyrosine kinase inhibitors (TKI) was received as the first-line therapy, but most patients eventually become resistant within 8–14 months (Yu et al., 2013).